Dr. Shao Li is a tenured professor at Tsinghua University, the director of TCM (traditional Chinese medicine)-X center, and the deputy director of Bioinformatics Division, BNRist. He proposed the “network target” concept and methodology to shift the “one target, one drug” approach, and is exploring a new way to the Precision Chinese Medicine on inflammation and cancer from a network and systems perspective. He is the founder of TCM network pharmacology, and the Chairman of Specialty committee of network pharmacology, World Federation of Chinese Medicine Societies (WFCMS). He published over 150 papers in leading journals such as Molecular Systems Biology, Cancer Research, and Cell Reports, which have been cited more than 4000 times. He held over 30 US and China patents. His works were highlighted by Nature China, F1000, and made the headline in The Wall Street Journal, which was selected as one of “The World top 10 news of TCM in 2014” by WFCMS. He was honored Li Shizhen Pharmaceutical Innovation Award (China Association of Chinese Medicine, 2019), National Ten-Thousand Talents Program (2019), National Outstanding Young Scientist Award (2012), Young and middle-aged leading talents in science and technology innovation (2018), National Science & Technology Award (2004), National Education Award (2009), and National Excellent Doctoral Dissertation (2003).

• Chapter 1. 'Network Target' Theory and Network Pharmacology.- Chapter 2. Application of Network Pharmacology Based on Artificial Intelligence Algorithm in Drug R & D.- Chapter 3. Commonly used Network Pharmacology Database.- Chapter 4. Commonly used Network Pharmacology Software.- Chapter 5. Network Pharmacology and TCM Modernization Case Studies.- Chapter 6. Network Pharmacology and Modern Drug R & D Cases.- Chapter 7. Drug-based Network Pharmacology Practice Process.- Chapter 8. Disease-based Network Pharmacology Practice Process.- Chapter 9. Drug-disease-based Network Pharmacology Practice Process.

Dr. Shao Li is a tenured professor at Tsinghua University, the director of TCM (traditional Chinese medicine)-X center, and the deputy director of Bioinformatics Division, BNRist. He proposed the “network target” concept and methodology to shift the “one target, one drug” approach, and is exploring a new way to the Precision Chinese Medicine on inflammation and cancer from a network and systems perspective. He is the founder of TCM network pharmacology, and the Chairman of Specialty committee of network pharmacology, World Federation of Chinese Medicine Societies (WFCMS). He published over 150 papers in leading journals such as Molecular Systems Biology, Cancer Research, and Cell Reports, which have been cited more than 4000 times. He held over 30 US and China patents. His works were highlighted by Nature China, F1000, and made the headline in The Wall Street Journal, which was selected as one of “The World top 10 news of TCM in 2014” by WFCMS. He was honored Li Shizhen Pharmaceutical Innovation Award (China Association of Chinese Medicine, 2019), National Ten-Thousand Talents Program (2019), National Outstanding Young Scientist Award (2012), Young and middle-aged leading talents in science and technology innovation (2018), National Science & Technology Award (2004), National Education Award (2009), and National Excellent Doctoral Dissertation (2003).

• Chapter 1. 'Network Target' Theory and Network Pharmacology.- Chapter 2. Application of Network Pharmacology Based on Artificial Intelligence Algorithm in Drug R & D.- Chapter 3. Commonly used Network Pharmacology Database.- Chapter 4. Commonly used Network Pharmacology Software.- Chapter 5. Network Pharmacology and TCM Modernization Case Studies.- Chapter 6. Network Pharmacology and Modern Drug R & D Cases.- Chapter 7. Drug-based Network Pharmacology Practice Process.- Chapter 8. Disease-based Network Pharmacology Practice Process.- Chapter 9. Drug-disease-based Network Pharmacology Practice Process.

Dr. Shao Li is a tenured professor at Tsinghua University, the director of TCM (traditional Chinese medicine)-X center, and the deputy director of Bioinformatics Division, BNRist. He proposed the “network target” concept and methodology to shift the “one target, one drug” approach, and is exploring a new way to the Precision Chinese Medicine on inflammation and cancer from a network and systems perspective. He is the founder of TCM network pharmacology, and the Chairman of Specialty committee of network pharmacology, World Federation of Chinese Medicine Societies (WFCMS). He published over 150 papers in leading journals such as Molecular Systems Biology, Cancer Research, and Cell Reports, which have been cited more than 4000 times. He held over 30 US and China patents. His works were highlighted by Nature China, F1000, and made the headline in The Wall Street Journal, which was selected as one of “The World top 10 news of TCM in 2014” by WFCMS. He was honored Li Shizhen Pharmaceutical Innovation Award (China Association of Chinese Medicine, 2019), National Ten-Thousand Talents Program (2019), National Outstanding Young Scientist Award (2012), Young and middle-aged leading talents in science and technology innovation (2018), National Science & Technology Award (2004), National Education Award (2009), and National Excellent Doctoral Dissertation (2003).

• Chapter 1. 'Network Target' Theory and Network Pharmacology.- Chapter 2. Application of Network Pharmacology Based on Artificial Intelligence Algorithm in Drug R & D.- Chapter 3. Commonly used Network Pharmacology Database.- Chapter 4. Commonly used Network Pharmacology Software.- Chapter 5. Network Pharmacology and TCM Modernization Case Studies.- Chapter 6. Network Pharmacology and Modern Drug R & D Cases.- Chapter 7. Drug-based Network Pharmacology Practice Process.- Chapter 8. Disease-based Network Pharmacology Practice Process.- Chapter 9. Drug-disease-based Network Pharmacology Practice Process.